Literature DB >> 36271235

Visual function and retinal changes after voretigene neparvovec treatment in children with biallelic RPE65-related inherited retinal dystrophy.

Francesco Testa1, Paolo Melillo1, Valentina Di Iorio2, Claudio Iovino1, Francesco Farinaro1, Marianthi Karali1,3, Sandro Banfi3,4, Settimio Rossi1, Michele Della Corte1, Francesca Simonelli1.   

Abstract

To report quantitative retinal changes assessed by spectral-domain optical coherence tomography (SD-OCT) in children treated with voretigene neparvovec (VN) at a single center in Italy. Retrospective review of six consecutive pediatric patients with biallelic RPE65-related dystrophy treated bilaterally with VN. SD-OCT scans were analyzed to extract Early Treatment Diabetic Retinopathy Study (ETDRS) thickness maps of the whole retina and the outer nuclear layer (ONL). Changes in visual function were assessed by best-corrected visual acuity (BCVA) and retinal morphology at Days 30/45 and 180. BCVA significantly improved at Day 30/45 and 6 months (both P < 0.001). Central foveal retinal thickness and central foveal ONL thickness tended to increase (6.4 ± 19.2 µm; P = 0.080 and 3.42 ± 7.68 µm; P = 0.091, respectively). ONL thickness of the internal ETDRS-ring significantly increased at day 30/45 (4.7 ± 8.4 µm; P < 0.001) and day 180 (5.0 ± 5.7 µm; P = 0.009). Intra-operative foveal detachment was not associated with a higher function gain in terms of BCVA, but with a mild thinning of foveal ONL after treatment. The improvement of BCVA and thickening of the ONL layer suggest that improvement of visual acuity could be related to partial recovery of retinal morphology in the perifoveal ring.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36271235     DOI: 10.1038/s41598-022-22180-6

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.996


  22 in total

1.  Genetics and phenotypes of RPE65 mutations in inherited retinal degeneration.

Authors:  D A Thompson; P Gyürüs; L L Fleischer; E L Bingham; C L McHenry; E Apfelstedt-Sylla; E Zrenner; B Lorenz; J E Richards; S G Jacobson; P A Sieving; A Gal
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

2.  Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle.

Authors:  T Michael Redmond; Eugenia Poliakov; Shirley Yu; Jen-Yue Tsai; Zhongjian Lu; Susan Gentleman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-06       Impact factor: 11.205

3.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.

Authors:  Stephen Russell; Jean Bennett; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Sarah McCague; Dominique Cross; Kathleen A Marshall; Jean Walshire; Taylor L Kehoe; Hannah Reichert; Maria Davis; Leslie Raffini; Lindsey A George; F Parker Hudson; Laura Dingfield; Xiaosong Zhu; Julia A Haller; Elliott H Sohn; Vinit B Mahajan; Wanda Pfeifer; Michelle Weckmann; Chris Johnson; Dina Gewaily; Arlene Drack; Edwin Stone; Katie Wachtel; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Albert M Maguire
Journal:  Lancet       Date:  2017-07-14       Impact factor: 79.321

4.  Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.

Authors:  Albert M Maguire; Stephen Russell; Jennifer A Wellman; Daniel C Chung; Zi-Fan Yu; Amy Tillman; Janet Wittes; Julie Pappas; Okan Elci; Kathleen A Marshall; Sarah McCague; Hannah Reichert; Maria Davis; Francesca Simonelli; Bart P Leroy; J Fraser Wright; Katherine A High; Jean Bennett
Journal:  Ophthalmology       Date:  2019-06-22       Impact factor: 12.079

5.  Five-year change in refractive error and its risk factors: results from the Gutenberg Health Study.

Authors:  Julia V Stingl; Sol A Ban; Markus Nagler; Irene Schmidtmann; Philipp S Wild; Karl J Lackner; Thomas Münzel; Manfred E Beutel; Norbert Pfeiffer; Alexander K Schuster
Journal:  Br J Ophthalmol       Date:  2021-08-06       Impact factor: 4.638

6.  Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or leber congenital amaurosis.

Authors:  H Morimura; G A Fishman; S A Grover; A B Fulton; E L Berson; T P Dryja
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

7.  Visual Acuity, Retinal Morphology, and Patients' Perceptions after Voretigene Neparovec-rzyl Therapy for RPE65-Associated Retinal Disease.

Authors:  Jesse D Sengillo; Ninel Z Gregori; Robert A Sisk; Christina Y Weng; Audina M Berrocal; Janet L Davis; Carlos E Mendoza-Santiesteban; D Diane Zheng; William J Feuer; Byron L Lam
Journal:  Ophthalmol Retina       Date:  2021-12-09

8.  Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.

Authors:  Callie Deng; Peter Y Zhao; Kari Branham; Dana Schlegel; Abigail T Fahim; Thiran K Jayasundera; Naheed Khan; Cagri G Besirli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-10       Impact factor: 3.535

9.  Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2.

Authors:  Francesco Testa; Albert M Maguire; Settimio Rossi; Eric A Pierce; Paolo Melillo; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; Carmela Acerra; J Fraser Wright; Jennifer Wellman; Katherine A High; Alberto Auricchio; Jean Bennett; Francesca Simonelli
Journal:  Ophthalmology       Date:  2013-03-06       Impact factor: 12.079

10.  Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial.

Authors:  Albert M Maguire; Katherine A High; Alberto Auricchio; J Fraser Wright; Eric A Pierce; Francesco Testa; Federico Mingozzi; Jeannette L Bennicelli; Gui-shuang Ying; Settimio Rossi; Ann Fulton; Kathleen A Marshall; Sandro Banfi; Daniel C Chung; Jessica I W Morgan; Bernd Hauck; Olga Zelenaia; Xiaosong Zhu; Leslie Raffini; Frauke Coppieters; Elfride De Baere; Kenneth S Shindler; Nicholas J Volpe; Enrico M Surace; Carmela Acerra; Arkady Lyubarsky; T Michael Redmond; Edwin Stone; Junwei Sun; Jennifer Wellman McDonnell; Bart P Leroy; Francesca Simonelli; Jean Bennett
Journal:  Lancet       Date:  2009-10-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.